Receptor-tuned Interleukin-2 Mutein Decouples Treg Expansion from ILC2-driven Cutaneous Inflammation
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci207126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Anupama Sahoo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Inflammation Research, Amgen Inc., South San Francisco, California, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Interleukin-2, Interleukin-2 Receptor alpha Subunit, Immunity, Innate. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen.
Abstract (Originalsprache)
Low-dose interleukin-2 (IL-2) and IL-2 muteins are being developed to expand regulatory T cells (Tregs) for autoimmune disease therapy, but injection site reactions (ISRs) remain frequent and poorly understood. Here we show IL2Mut24, a murine surrogate of IL-2 receptor α (IL-2Rα, CD25)-biased IL-2 mutein, enhances Treg expansion yet paradoxically exacerbates cutaneous inflammation compared to wild-type IL-2. Using immunodeficient mice, antibody blockade and adoptive transfer, we identify group 2 innate lymphoid cells (ILC2s) as key drivers of IL-2-induced skin inflammation, defining a CD25-dependent innate activation axis that constrains immune tolerance. In cynomolgus monkeys, the CD25-biased IL-2 mutein efavaleukin alfa promotes greater peripheral Treg expansion than aldesleukin (recombinant human IL-2) but is accompanied by transient increases in IL-5 and dose-dependent ISRs, indicating conservation of this innate inflammatory program across species. To improve the therapeutic window, we engineer receptor clamps by linking IL2Mut24 to antibodies against CD25 to restrict IL-2 access to CD25. This receptor-tuned IL-2 preserves Treg selectivity, suppresses ISRs, and outperforms IL2Mut24 in experimental autoimmune encephalomyelitis by restraining Th17 responses. These findings reveal a conserved innate mechanism underlying IL-2–associated toxicity and establish receptor-tuning as a strategy to improve the safety and efficacy of IL-2–based immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Inflammation Research, Amgen Inc., South San Francisco, California, USA.
- Amgen R&D Postdoctoral Fellows Program, South San Francisco, California, USA.
- Discovery Sciences, Advanced Technologies & AI, Amgen Inc., South San Francisco, California, USA.
- Discovery Protein Science, Amgen Inc., South San Francisco, California, USA.
- Translational Safety & Risk Sciences, Amgen Inc., Cambridge, Massachusetts, USA.
- Pharmacokinetics and Drug Metabolism, Amgen Inc., South San Francisco, California, USA.
Förderung
- Amgen
Zitieren
APA
Sahoo, A., Moorman, C., Tsenkova, M., Jing, Y., Valdovinos, A., Luo, X., Lu, S., Wang, S., Hukkanen, R. R., Fort, M., Tang, H. S., Primack, R., Mandavalli, S., & Deng, W. (2026). Receptor-tuned Interleukin-2 Mutein Decouples Treg Expansion from ILC2-driven Cutaneous Inflammation. Journal of Clinical Investigation. https://doi.org/10.1172/jci207126
Vancouver
Sahoo A, Moorman C, Tsenkova M, Jing Y, Valdovinos A, Luo X, et al. Receptor-tuned Interleukin-2 Mutein Decouples Treg Expansion from ILC2-driven Cutaneous Inflammation. Journal of Clinical Investigation. 2026. doi:10.1172/jci207126
BibTeX
@article{Sahoo2026,
author = {Sahoo, Anupama and Moorman, Cody and Tsenkova, Mina and Jing, Yi and Valdovinos, Alexis and Luo, Xin and Lu, Shiping and Wang, Songyu and Hukkanen, Renee R and Fort, Madeline and Tang, Helen S and Primack, Ronya and Mandavalli, Shweta and Deng, Weiwen},
title = {Receptor-tuned Interleukin-2 Mutein Decouples Treg Expansion from ILC2-driven Cutaneous Inflammation},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci207126}
}
EUVIMED